Ligand Pharmaceuticals Incorporated (LGND)
Total asset turnover
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (ttm) | US$ in thousands | 167,133 | 152,422 | 133,478 | 118,313 | 131,314 | 153,595 | 186,815 | 217,868 | 219,582 | 241,673 | 240,420 | 267,676 | 277,133 | 274,650 | 251,663 | 208,408 | 186,419 | 143,432 | 126,392 | 109,959 |
Total assets | US$ in thousands | 941,774 | 954,866 | 866,405 | 913,869 | 833,064 | 769,210 | 758,105 | 811,076 | 762,668 | 1,051 | 1,076,290 | 1,105,180 | 1,301,380 | 1,273,660 | 1,256,280 | 1,295,120 | 1,362,280 | 1,247,450 | 1,242,940 | 1,185,920 |
Total asset turnover | 0.18 | 0.16 | 0.15 | 0.13 | 0.16 | 0.20 | 0.25 | 0.27 | 0.29 | 229.95 | 0.22 | 0.24 | 0.21 | 0.22 | 0.20 | 0.16 | 0.14 | 0.11 | 0.10 | 0.09 |
December 31, 2024 calculation
Total asset turnover = Revenue (ttm) ÷ Total assets
= $167,133K ÷ $941,774K
= 0.18
Ligand Pharmaceuticals Incorporated's total asset turnover ratio has shown fluctuating trends over the past few years. The ratio increased from 0.09 on March 31, 2020, to a peak of 0.29 on December 31, 2022. However, after reaching its highest point, it decreased to 0.18 by December 31, 2024.
Overall, the company's total asset turnover ratio indicates how efficiently it is utilizing its assets to generate revenue. It is essential to monitor this ratio closely to assess the effectiveness of Ligand Pharmaceuticals in generating sales relative to its total assets.
Peer comparison
Dec 31, 2024
Company name
Symbol
Total asset turnover
Ligand Pharmaceuticals Incorporated
LGND
0.18
Abbott Laboratories
ABT
0.52
AbbVie Inc
ABBV
0.42
ACADIA Pharmaceuticals Inc
ACAD
0.81
Alkermes Plc
ALKS
0.75
Amphastar P
AMPH
0.46
ANI Pharmaceuticals Inc
ANIP
0.48
Arcus Biosciences Inc
RCUS
0.22
Biomarin Pharmaceutical Inc
BMRN
0.40
Bristol-Myers Squibb Company
BMY
0.52
Catalyst Pharmaceuticals Inc
CPRX
0.58